Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Feb;95(2):224-225.
doi: 10.1002/ccd.28751.

Bioresorbable scaffold: Never say never

Giuseppe Musumeci  1 , Giorgio Baralis  1
Affiliations
Editorial

Bioresorbable scaffold: Never say never

Giuseppe Musumeci et al. Catheter Cardiovasc Interv. 2020 Feb.

Abstract

Bioresorbable vascular scaffolds (BVSs) were designed to overcome the limitations of metallic stents. Absorb BVS has provided information about strut thickness, scaffold degradation, vessel wall coverage, and their influence on thrombosis. Clinical trials have shown higher rates of target vessel myocardial infarction and stent thrombosis with the absorb BVS than with second-generation drug-eluting stents.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Kawamoto H, Jabbour RJ, Tanaka A, Latib A, Colombo A. The bioresorbable scaffold: will oversizing affect outcomes? JACC Cardiovasc Interv. 2016;9(3):299-300.
    1. Baber U, Mehran R, Sharma SK, Brar S, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58(15):1569-1577.
    1. Goel S, Pasam RT, Chava S, Sharma A. 3-4 year outcomes of the absorb bioresorbable vascular scaffold versus second generation drug eluting stent: a meta-analysis. Catheter Cardiovasc Interv. 2020;95:216-223.
    1. Sorrentino S, Giustino G, Mehran R, et al. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. J Am Coll Cardiol. 2017;69:3055-3066.
    1. Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387:537-544.

LinkOut - more resources